Bridging genomics and the environment to revolutionize the diagnosis and treatment of complex health conditions
A substantial need exists for new biomarkers, especially for CNS conditions and GI disorders caused by the interplay of genetics and the environment. Extensive research in these areas has yet to result in genetic tests to guide diagnosis and treatment choices. Without biological tests, doctors continue to rely on questionnaires and specialists’ observations of symptoms for their clinical decision-making.
With its unique temporal exposomic platform, LinusBio can detect complex biomolecular signals in human hair. These signatures map metabolic responses to environmental inputs and can provide objective information to diagnose disease, stratify patient cohorts for clinical trials, and objectively measure study results.
Central Nervous System
Patent
submitted
Clinical
studies
Pathway
characterization
Commercially
Available
Status: CLIA granted
ClearStrand-ASD is a non-invasive test that detects a biomarker associated with autism using a strand of hair. It is the first and only objective laboratory test for autism proven to be valid for children who are 1 month up to 36 months of age.
Central Nervous System
Patent
submitted
Clinical
studies
Pathway
characterization
Commercially
Available
Status: Enrollment ongoing
ADHD reduces people’s ability to focus, makes them more active and impulsive and is usually diagnosed through interviews and psychological tests. LinusBio’s diagnostic would be the first molecular test for ADHD, providing precise information to diagnose patients and test new therapies in clinical trials.
Central Nervous System
Patent
submitted
Clinical
studies
Pathway
characterization
Commercially
Available
Status: Enrollment ongoing
Psychosis and schizophrenia are chronic neurological disease that can cause delusions, hallucinations, and other behavioral issues. There are effective therapies in the clinic, but the first step is diagnosis. At this moment, there are no molecular diagnostics for these conditions – LinusBio’s would be the first.
Central Nervous System
Patent
submitted
Clinical
studies
Pathway
characterization
Commercially
Available
Status: FDA discussion initiated
ALS destroys the neurons that control muscle movement. As motor neurons die, muscles atrophy and weaken. Eventually, patients can no longer walk, talk or breath. ALS is currently diagnosed through multiple tests, with no definitive diagnostic. With a single strand of hair, LinusBio’s diagnostic platform can vastly accelerate and simplify the diagnostic process.
Gut
Patent
submitted
Clinical
studies
Pathway
characterization
Commercially
Available
Status: Enrollment ongoing
IBS and eosinophilic esophagitis are chronic and painful conditions often caused by a person’s interactions with their environment. Exposomic readouts can help delineate underlying causes, providing a clinical strategy to help control these conditions.
Cancer
Patent
submitted
Clinical
studies
Pathway
characterization
Commercially
Available
Status: Enrollment ongoing
Cancers respond best to treatment when they are detected early and that is particularly true for pediatric tumors. Exposomic data identifies the body’s response to malignancies, providing a roadmap for further care.
Data
Patent
submitted
Clinical
studies
Pathway
characterization
Commercially
Available
Status: 1K complete, growing to 100K
Just like genomic information, which grows increasingly valuable as more gene variations and regulatory features are discovered, exposomic data gains value as it matures. LinusBio’s growing exposomic dataset is helping us develop a biomarker-based platform for multiple applications.
In addition, biopharma companies can use this dataset to optimize clinical trial recruitment, set objective study endpoints, open new windows into patient compliance and drug pharmacology and solve many other problems.
Wellness
Patent
submitted
Clinical
studies
Pathway
characterization
Commercially
Available
Status: Prototype complete for total analysis
People are often exposed to heavy metals, noxious gases and other toxins – both out in the world and in their own homes. LinusBio’s exposomic platform reads the body’s metabolic responses to these exposures, providing insights that could inform remediation, detoxification and other measures.
LinusBio’s platform generates data that would normally require hundreds of sequential blood tests – in one assay. These molecular signatures are being used to develop in-depth diagnostics for ASD and many other conditions.
Novel biomarkers deliver new angles on health and synergize with genomic and other diagnostic tests.
The platform delivers objective biomarkers for CNS disorders and other complex health conditions. Early detection often translates into more effective interventions.
